0000950170-24-080497.txt : 20240702 0000950170-24-080497.hdr.sgml : 20240702 20240702162009 ACCESSION NUMBER: 0000950170-24-080497 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240627 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240702 DATE AS OF CHANGE: 20240702 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ATOSSA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001488039 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 264753208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35610 FILM NUMBER: 241095638 BUSINESS ADDRESS: STREET 1: 107 SPRING STREET CITY: SEATTLE STATE: WA ZIP: 98104 BUSINESS PHONE: 206.588.0256 MAIL ADDRESS: STREET 1: 107 SPRING STREET CITY: SEATTLE STATE: WA ZIP: 98104 FORMER COMPANY: FORMER CONFORMED NAME: ATOSSA GENETICS INC DATE OF NAME CHANGE: 20100325 8-K 1 atos-20240627.htm 8-K 8-K
0001488039--12-31false00014880392024-06-272024-06-270001488039dei:FormerAddressMember2024-06-272024-06-27

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 27, 2024

 

Atossa Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

Delaware

001-35610

26-4753208

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

10202 5th Avenue NE

Suite 200

Seattle, Washington

98125

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 588-0256

107 Spring Street

Seattle, Washington 98104

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading
Symbol(s)


Name of each exchange on which registered

Common Stock, $0.18 par value

ATOS

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

 


 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


 

On June 27, 2024, Atossa Therapeutics, Inc., a Delaware corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on May 9, 2024, the record date for the Annual Meeting, there were 125,757,416 shares of common stock, par value $0.18 per share (the “Common Stock”), entitled to vote at the meeting.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Amendment and Restatement of the Company’s 2020 Stock Incentive Plan, As Amended

 

At the Annual Meeting, the Company’s stockholders approved an amendment and restatement of the Company’s 2020 Stock Incentive Plan, as amended (the “2020 Plan”), and increased the shares available for issuance by 12,000,000 shares and extended the term thereof.

 

For additional information regarding the 2020 Plan, please refer to the heading “Summary Description of the 2020 Plan” contained in Proposal 3 of the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on May 23, 2024 (the “Proxy Statement”).

 

The foregoing description of the 2020 Plan and the summary contained in the Proxy Statement do not purport to be complete and are qualified in their entirety by reference to the full text of the 2020 Plan, a copy of which is attached hereto as Exhibit 10.1.

 

Appointment of Chief Financial Officer

 

On June 27, 2024, the Board of Directors (the “Board”) of the Company appointed Heather Rees, previously the Company’s Senior Vice President, Finance and Accounting, to serve as Chief Financial Officer and to continue serving as principal financial and accounting officer, effective immediately.

 

In connection with Ms. Rees’ appointment, the Board approved an increase to her annual base salary to $439,700 and an increase to her target annual cash bonus amount to 40% of her base salary, subject to the achievement of annual performance milestones to be established by the Board. The Company has granted Ms. Rees 577,700 options to purchase shares of Common Stock, which will vest on a quarterly basis over two years and was granted pursuant to, and subject to the terms and conditions of, the 2020 Plan. The Company and Ms. Rees intend to enter into an employment agreement to reflect the above terms.

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

At the Annual Meeting, the Company’s stockholders also approved an amendment of the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to increase the number of authorized shares of Common Stock from 175,000,000 to 350,000,000, which also has the effect of increasing the total number of authorized shares from 185,000,000 to 360,000,000 (the “Amendment”).

 

On June 28, 2024, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Amendment, which became effective immediately upon such filing.

 

The foregoing description of the Amendment does not purport to be complete and is subject to and qualified in its entirety by reference to the Certificate of Amendment, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

 

 

 


 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

At the Annual Meeting, each of the Company’s director nominees was elected and each of the other proposals voted on was approved. The final voting results are set forth below.

 

(i)
Election of Two Class III Directors

The stockholders elected the two Class III directors by the following votes:

 

Nominee

Votes
For

Votes
Withheld

Broker

Non-Votes

Shu-Chih Chen, Ph.D.

28,619,224

3,778,904

27,879,201

H. Lawrence Remmel, Esq.

28,453,128

3,864,924

27,959,277

 

(ii)
Ratification of Independent Auditor

The stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 by the following votes:

 

Votes
For

Votes
Against

Abstentions

Broker

Non-Votes

58,330,064

1,449,110

498,155

0

 

(iii)
Approval of an Amendment and Restatement of the 2020 Plan

 

The stockholders approved an amendment and restatement of the 2020 Plan by the following votes:

 

Votes
For

Votes
Against

Abstentions

Broker

Non-Votes

20,792,908

10,620,891

904,253

27,959,277

 

(iv)
Approval of an Amendment of the Certificate of Incorporation

 

The stockholders approved an amendment of the Certificate of Incorporation by the following votes:

 

Votes
For

Votes
Against

Abstentions

Broker

Non-Votes

44,552,602

15,094,316

630,411

0

 

(v)
Advisory Vote on Executive Compensation

 

The stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers by the following votes:

 

Votes
For

Votes
Against

Abstentions

Broker

Non-Votes

23,453,687

7,079,748

1,784,257

27,959,637

 

 

 


 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

 

 

Exhibit No.

 

Description

3.1

 

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Atossa Therapeutics, Inc.

 

 

 

10.1

 

Atossa Therapeutics, Inc. 2020 Stock Incentive Plan, as Amended

 

 

 

104

 

Cover page Interactive Data File (embedded within the Inline XBRL document)

 

* * *

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Atossa Therapeutics, Inc.

Date:

July 2, 2024

By:

/s/ Heather Rees

Heather Rees
Senior Vice President, Finance & Accounting

 

 


EX-3.1 2 atos-ex3_1.htm EX-3.1 EX-3.1

 

Exhibit 3.1

 

CERTIFICATE OF AMENDMENT

TO THE

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF ATOSSA THERAPEUTICS, INC.

 

Atossa Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows:

FIRST: That the current name of the Corporation is Atossa Therapeutics, Inc., and the Corporation was originally incorporated pursuant to the General Corporation Law of the State of Delaware (the “DGCL”) on April 30, 2009 under the name Atossa Genetics Inc.

SECOND: That the Corporation’s Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on November 8, 2012 (as subsequently amended, the “Certificate of Incorporation”).

THIRD: That pursuant to and in accordance with Section 242 of the DGCL, this Certificate of Amendment hereby further amends the provisions of the Certificate of Incorporation as follows:

a. The first paragraph of the “Capital Stock” section of Article IV is hereby amended and restated to read as follows:

“The total number of shares of capital stock which the Corporation shall have authority to issue is Three Hundred Sixty Million (360,000,000) shares, consisting of Three Hundred Fifty Million (350,000,000) shares of common stock, par value $0.18 per share (the “Common Stock”), and Ten Million (10,000,000) shares of preferred stock, par value $0.001 per share (the “Undesignated Preferred Stock”).”

FOURTH: This Certificate of Amendment to the Certificate of Incorporation was duly authorized and adopted by the Corporation’s Board of Directors (the “Board”) and stockholders in accordance with the provisions of Section 242 of the DGCL.

FIFTH: This Certificate of Amendment to the Certificate of Incorporation shall be effective immediately upon filing with the Secretary of State of the State of Delaware.

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to the Certificate of Incorporation to be executed by Steven C. Quay, M.D., Ph.D., its Chairman of the Board, President and Chief Executive Officer, this 27th day of June 2024.

 

ATOSSA THERAPEUTICS, INC.

 


 

By: /s/ Steven C. Quay

Name: Steven C. Quay, M.D., Ph.D.

Title: Chairman of the Board, President and Chief Executive Officer

2


EX-10.1 3 atos-ex10_1.htm EX-10.1 EX-10.1

 

Exhibit 10.1

 

ATOSSA THERAPEUTICS, INC.
2020 STOCK INCENTIVE PLAN
(Most Recently Amended effective as of June 27, 2024)

SECTION 1.
GENERAL PURPOSE OF THE PLAN; DEFINITIONS

The name of the plan is the Atossa Therapeutics, Inc. 2020 Stock Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and other key persons (including Consultants and prospective employees) of Atossa Therapeutics, Inc. (the “Company”) and its Subsidiaries upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company.

The following terms shall be defined as set forth below:

Act” means the Securities Act of 1933, as amended, and the rules and regulations thereunder.

Administrator” means either the Board or the compensation committee of the Board or a similar committee performing the functions of the compensation committee and which is comprised of not less than two Non-Employee Directors, each of whom is intended to qualify as both a “non-employee director” as defined by Rule 16b-3 of the Exchange Act or any successor rule and an “independent director” under the rules of any national securities exchange or automated quotation system on which the Stock is listed, quoted or traded; provided that any action taken by such committee shall be valid and effective, whether or not the members of such committee at the time of such action are later determined not to have satisfied the requirements for membership set forth in this definition or otherwise provided in any charter of such committee.

Award” or “Awards,” except where referring to a particular category of grant under the Plan, shall include Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards, Cash-Based Awards, Performance Share Awards and Dividend Equivalent Rights.

Award Certificate” means a written or electronic document setting forth the terms and provisions applicable to an Award granted under the Plan. Each Award Certificate is subject to the terms and conditions of the Plan.

Board” means the Board of Directors of the Company.

Cash-Based Award” means an Award entitling the recipient to receive a cash-denominated payment.

Change in Control” means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:

(a)
A transaction or series of transactions (other than an offering of Stock to the general public through a registration statement filed with the Securities and Exchange Commission) whereby any “person” or related “group” of “persons” (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its subsidiaries, an employee benefit plan maintained by the Company or any of its subsidiaries or a “person” that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company’s securities outstanding immediately after such acquisition; or
(b)
During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new member(s) of the Board (other than a member of the Board designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsection (a) or subsection (c) of this definition) whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds of the members of the Board then still in office who either were members of

 


 

the Board at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or
(c)
The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the Company’s assets in any single transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction:
(i)
which results in the Company’s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company’s assets or otherwise succeeds to the business of the Company (the Company or such person, the “Successor Entity”)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity’s outstanding voting securities immediately after the transaction, and
(ii)
after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity; provided, however, that no person or group shall be treated for purposes of this subsection (ii) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction; or
(d)
The Company’s stockholders approve a liquidation or dissolution of the Company.

Notwithstanding the foregoing, if a Change in Control constitutes a payment event with respect to any portion of an Award that provides for the deferral of compensation and is subject to Section 409A of the Code, the transaction or event described in subsection (a), (b), (c) or (d) with respect to such Award (or portion thereof) must also constitute a “change in control event,” as defined in Treasury Regulation Section 1.409A-3(i)(5) to the extent required by Section 409A. The Committee shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control of the Company has occurred pursuant to the above definition, and the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority is in conjunction with a determination of whether a Change in Control is a “change in control event” as defined in Treasury Regulation Section 1.409A-3(i)(5) shall be consistent with such regulation.

Code” means the Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations.

Consultant” means any natural person that provides bona fide services to the Company, and such services are not in connection with the offer or sale of securities in a capital-raising transaction and do not directly or indirectly promote or maintain a market for the Company’s securities.

Dividend Equivalent Right” means an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee.

Effective Date” means the date on which the Plan is approved by stockholders as set forth in Section 21.

Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.

Fair Market Value” of the Stock on any given date means the fair market value of the Stock determined in good faith by the Administrator; provided, however, that if the Stock is admitted to quotation on the National Association of Securities Dealers Automated Quotation System (“NASDAQ”), NASDAQ Global Market or another national securities exchange, the determination shall be made by reference to market quotations. If there are no market quotations for such date, the determination shall be made by reference to the last date preceding such date for which there are market quotations.

Incentive Stock Option” means any Stock Option designated and qualified as an “incentive stock option” as defined in Section 422 of the Code.

 


 

Non-Employee Director” means a member of the Board who is not also an employee of the Company or any Subsidiary.

Non-Qualified Stock Option” means any Stock Option that is not an Incentive Stock Option.

Option” or “Stock Option” means any option to purchase shares of Stock granted pursuant to Section 5.

Performance Criteria” means the criteria that the Administrator selects for purposes of establishing the Performance Goal or Performance Goals for an individual for a Performance Cycle. The Performance Criteria (which shall be applicable to the organizational level specified by the Administrator, including, but not limited to, the Company or a unit, division, group, or Subsidiary of the Company) that will be used to establish Performance Goals may include one or more of the following: earnings before interest, taxes, depreciation and amortization, net income (loss) (either before or after interest, taxes, depreciation and/or amortization), changes in the market price of the Stock, economic value-added, funds from operations or similar measure, sales or revenue, acquisitions or strategic transactions, operating income (loss), cash flow (including, but not limited to, operating cash flow and free cash flow), return on capital, assets, equity, or investment, stockholder returns, return on sales, gross or net profit levels, productivity, expense, margins, operating efficiency, customer satisfaction, working capital, earnings (loss) per share of Stock, sales or market shares and number of customers, any other criteria deemed appropriate by the Committee, any of which may be measured either in absolute terms or as compared to any incremental increase or as compared to results of a peer group.

Performance Cycle” means one or more periods of time, which may be of varying and overlapping durations, as the Administrator may select, over which the attainment of one or more Performance Criteria will be measured for the purpose of determining a grantee’s right to and the payment of a Restricted Stock Award, Restricted Stock Units, Performance Share Award or Cash-Based Award.

Performance Goals” means, for a Performance Cycle, the specific goals established in writing by the Administrator for a Performance Cycle based upon the Performance Criteria.

Performance Share Award” means an Award entitling the recipient to acquire shares of Stock upon the attainment of specified Performance Goals.

Prior Plan” means the Atossa Genetics, Inc. 2010 Stock Option and Incentive Plan, as amended from time to time.

Restricted Stock Award” means an Award entitling the recipient to acquire, at such purchase price (which may be zero) as determined by the Administrator, shares of Stock subject to such restrictions and conditions as the Administrator may determine at the time of grant.

Restricted Stock Unit” means a contractual right to receive in the future a share of Stock or the Fair Market Value of a Share of Stock in cash.

Sale Price” means the value of the consideration payable, or otherwise to be received by stockholders, per share of Stock in connection with a Change in Control.

Section 409A” means Section 409A of the Code and the regulations and other guidance promulgated thereunder.

Stock” means the Common Stock, par value $0.18 per share, of the Company, subject to adjustments pursuant to Section 3.

Stock Appreciation Right” means an Award entitling the recipient to receive shares of Stock having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.

Subsidiary” means any corporation or other entity (other than the Company) in which the Company has at least a 50 percent interest, either directly or indirectly.

 


 

Ten Percent Owner” means an employee who owns or is deemed to own (by reason of the attribution rules of Section 424(d) of the Code) more than 10 percent of the combined voting power of all classes of stock of the Company or any parent or subsidiary corporation.

Unrestricted Stock Award” means an Award of shares of Stock free of any restrictions.

SECTION 2.
ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS
(a)
Administration of Plan.
(i)
The Plan shall be administered by the Administrator. Notwithstanding the foregoing, (A) the full Board, acting by a majority of its members in office, shall conduct the general administration of the Plan with respect to Awards granted to Non-Employee Directors and, with respect to such Awards, the term “Administrator” as used in the Plan shall be deemed to refer to the Board and (B) the Administrator may delegate its authority hereunder to the extent permitted by Section 2(a)(ii).
(ii)
To the extent permitted by applicable laws, the Administrator may from time to time delegate to a committee of one or more members of the Board or one or more officers of the Company the authority to grant or amend Awards or to take other administrative actions pursuant to this Section 2; provided, however, that in no event shall an officer of the Company be delegated the authority to grant awards to, or amend awards held by, the following individuals: (A) individuals who are subject to Section 16 of the Exchange Act or (B) officers of the Company (or members of the Board) to whom authority to grant or amend Awards has been delegated hereunder; provided, further, that any delegation of administrative authority shall only be permitted to the extent it is permissible under applicable laws. Any delegation hereunder shall be subject to the restrictions and limits that the Administrator specifies at the time of such delegation, and the Administrator may at any time rescind the authority so delegated or appoint a new delegatee. At all times, the delegatee appointed under this Section 2(a)(ii) shall serve in such capacity at the pleasure of the Administrator.
(b)
Powers of Administrator. The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan, including the power and authority:
(i)
to select the individuals to whom Awards may from time to time be granted;
(ii)
to determine the time or times of grant, and the extent, if any, of Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, Cash-Based Awards, Performance Share Awards and Dividend Equivalent Rights, or any combination of the foregoing, granted to any one or more grantees;
(iii)
to determine the number of shares of Stock to be covered by any Award subject to the limitations set forth in Section 2(f), Section 3(a) and Section 5(e);
(iv)
to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Certificates;
(v)
to accelerate at any time the exercisability or vesting of all or any portion of any Award; subject to the provisions of Section 5(b), to extend at any time the period in which Stock Options may be exercised; and
(vi)
at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan.

Notwithstanding the foregoing, the Administrator shall not, without the approval of the stockholders of the Company, have the authority to (i) amend any outstanding Incentive Stock Option, Non-Qualified Stock Option or Stock Appreciation Right to reduce its exercise price, or (ii) cancel any Incentive Stock Option, Non-Qualified Stock Option or

 


 

Stock Appreciation Right in exchange for cash or another Award when the Incentive Stock Option, Non-Qualified Stock Option or Stock Appreciation Right exercise price exceeds the Fair Market Value of the underlying shares of Stock. All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees.

(c)
Award Certificate. Awards under the Plan shall be evidenced by Award Certificates that set forth the terms, conditions and limitations for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event employment or service terminates.
(d)
Indemnification. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys’ fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company’s articles or bylaws or any directors’ and officers’ liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company.
(e)
Foreign Award Recipients. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in which the Company and its Subsidiaries operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to: (i) determine which Subsidiaries shall be covered by the Plan; (ii) determine which individuals outside the United States are eligible to participate in the Plan; (iii) modify the terms and conditions of any Award granted to individuals outside the United States to comply with applicable foreign laws; (iv) establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and/or modifications shall be attached to this Plan as appendices); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section 3(a) hereof; and (v) take any action, before or after an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law.
SECTION 3.
STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION
(a)
Stock Issuable. The aggregate number of shares of Stock that may be issued pursuant to Awards granted under the Plan shall be 30,000,000 shares (subject to any increase or decrease pursuant to Section 3(b) and Section 3(c)) plus (i) any shares of Stock that remain available for grant under the Prior Plan as of the Effective Date and (ii) any shares of Stock underlying any awards under the Prior Plan that, on or after the Effective Date, are forfeited, canceled, held back upon exercise of an Option or settlement of such an award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, or satisfied without the issuance of Stock or otherwise terminated (other than by exercise). Shares of Stock issued pursuant to Awards granted under the Plan may be either authorized and unissued Stock or Stock held in or acquired for the treasury of the Company or both. The maximum number of shares of Stock with respect to which Incentive Stock Options may be granted under the Plan shall be 30,000,000 shares. For purposes of the maximum number of shares limit, the shares of Stock underlying any Awards that are forfeited, canceled, held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) shall be added back to the shares of Stock available for issuance under the Plan. In the event the Company repurchases shares of Stock on the open market, such shares shall not be added to the shares of Stock available for issuance under the Plan. Subject to such overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or types of Award; provided, however, that, other than in the case of Non-Employee Directors, Stock Options or Stock Appreciation Rights with respect to no more than 2,500,000 may be granted to any one individual grantee during any one calendar year period.
(b)
Changes in Stock. Subject to Section 3(c) hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Company’s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Stock or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i) the maximum number of shares reserved for

 


 

issuance under the Plan, including the maximum number of shares that may be issued in the form of Incentive Stock Options, (ii) the number of Stock Options or Stock Appreciation Rights that can be granted to any one individual grantee, (iii) the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iv) the repurchase price, if any, per share subject to each outstanding Restricted Stock Award, and (v) the exercise price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares.
(c)
Change in Control and Other Transactions. Except as the Administrator may otherwise specify with respect to particular Awards in the relevant Award Certificate, in the case of and subject to the consummation of a Change in Control, the Plan and all outstanding Awards granted hereunder shall terminate, unless provision is made in connection with the Change in Control in the sole discretion of the parties thereto for the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree (after taking into account any acceleration hereunder). In the event of such termination, (i) the Company shall have the option (in its sole discretion) to make or provide for a cash payment to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A) the Sale Price multiplied by the number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable (after taking into account any acceleration hereunder) at prices not in excess of the Sale Price) and (B) the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights; or (ii) each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights held by such grantee. The Administrator shall also have the discretion to accelerate the vesting of all other Awards.
(d)
Substitute Awards. The Administrator may grant Awards under the Plan in substitution for stock and stock based awards held by employees, directors or other service providers of another corporation in connection with the merger or consolidation of the employing corporation with the Company or a Subsidiary or the acquisition by the Company or a Subsidiary of property or stock of the employing corporation. The Administrator may direct that the substitute awards be granted on such terms and conditions as the Administrator considers appropriate in the circumstances. Any substitute Awards granted under the Plan shall not count against the share limitation set forth in Section 3(a).
SECTION 4.
ELIGIBILITY

Grantees under the Plan will be such full or part-time officers and other employees, Non-Employee Directors and key persons (including Consultants and prospective employees) of the Company and its Subsidiaries as are selected from time to time by the Administrator in its sole discretion.

SECTION 5.
STOCK OPTIONS

Any Stock Option granted under the Plan shall be in such form as the Administrator may from time to time approve.

Stock Options granted under the Plan may be either Incentive Stock Options or Non-Qualified Stock Options. Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a “subsidiary corporation” within the meaning of Section 424(f) of the Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a Non-Qualified Stock Option.

Stock Options granted pursuant to this Section 5 shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable. If the Administrator so determines, Stock Options may be granted in lieu of cash compensation at the optionee’s election, subject to such terms and conditions as the Administrator may establish.

(a)
Exercise Price. The exercise price per share for the Stock covered by a Stock Option granted pursuant to this Section 5 shall be determined by the Administrator at the time of grant but shall not be less than 100

 


 

percent of the Fair Market Value on the date of grant. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the option price of such Incentive Stock Option shall be not less than 110 percent of the Fair Market Value on the grant date.
(b)
Option Term. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than ten years after the date the Stock Option is granted. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years from the date of grant.
(c)
Exercisability; Rights of a Stockholder. Stock Options shall become exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the grant date. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options.
(d)
Method of Exercise. Stock Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods to the extent provided in the Option Award Certificate:
(i)
In cash, by certified or bank check or other instrument acceptable to the Administrator;
(ii)
Through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the optionee on the open market or that have been beneficially owned by the optionee for at least six months and that are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date;
(iii)
By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; or
(iv)
With respect to Stock Options that are not Incentive Stock Options, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price.

Payment instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full purchase price for such shares and the fulfillment of any other requirements contained in the Option Award Certificate or applicable provisions of laws (including the satisfaction of any withholding taxes that the Company is obligated to withhold with respect to the optionee). In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option shall be net of the number of attested shares. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated system.

(e)
Annual Limit on Incentive Stock Options. To the extent required for “incentive stock option” treatment under Section 422 of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the shares of Stock with respect to which Incentive Stock Options granted under this Plan and any other plan of the Company or its parent and subsidiary corporations become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000. To the extent that any Stock Option exceeds this limit, it shall constitute a Non-Qualified Stock Option.
SECTION 6.
STOCK APPRECIATION RIGHTS
(a)
Exercise Price of Stock Appreciation Rights. The exercise price of a Stock Appreciation Right shall not be less than 100 percent of the Fair Market Value of the Stock on the date of grant.

 


 

(b)
Grant and Exercise of Stock Appreciation Rights. Stock Appreciation Rights may be granted by the Administrator independently of any Stock Option granted pursuant to Section 5 of the Plan.
(c)
Terms and Conditions of Stock Appreciation Rights. Stock Appreciation Rights shall be subject to such terms and conditions as shall be determined from time to time by the Administrator. The term of a Stock Appreciation Right may not exceed ten years.
(d)
Exercisability; Rights of a Stockholder. Stock Appreciation Rights shall become exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the grant date. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Appreciation Rights. A grantee shall have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Appreciation Right and not as to unexercised Stock Appreciation Rights.
(e)
Method of Exercise. Stock Appreciation Rights may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods to the extent provided in the Stock Appreciation Rights Award Certificate:
(i)
In cash, by certified or bank check or other instrument acceptable to the Administrator;
(ii)
Through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the grantee on the open market or that have been beneficially owned by the grantee for at least six months and that are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date;
(iii)
By the grantee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the grantee chooses to pay the purchase price as so provided, the grantee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; or
(iv)
By a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price.

Payment instruments will be received subject to collection. The transfer to the grantee on the records of the Company or of the transfer agent of the shares of Stock to be purchased pursuant to the exercise of a Stock Appreciation Right will be contingent upon receipt from the grantee (or a purchaser acting in his stead in accordance with the provisions of the Stock Appreciation Right) by the Company of the full purchase price for such shares and the fulfillment of any other requirements contained in the Stock Appreciation Rights Award Certificate or applicable provisions of laws (including the satisfaction of any withholding taxes that the Company is obligated to withhold with respect to the grantee). In the event an grantee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the grantee upon the exercise of the Stock Appreciation Right shall be net of the number of attested shares. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Appreciation Rights, such as a system using an internet website or interactive voice response, then the paperless exercise of Stock Appreciation Rights may be permitted through the use of such an automated system.

SECTION 7.
RESTRICTED STOCK AWARDS
(a)
Nature of Restricted Stock Awards. The Administrator shall determine the restrictions and conditions applicable to each Restricted Stock Award at the time of grant. Conditions may be based on continuing employment (or other service relationship) and/or achievement of pre-established performance goals and objectives. The terms and conditions of each such Award Certificate shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees.
(b)
Rights as a Stockholder; Certificates for Restricted Stock. Upon the grant of the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to

 


 

the voting of the Restricted Stock, subject to such conditions contained in the Restricted Stock Award Certificate. Restricted Stock granted pursuant to the Plan may be evidenced in such manner as the Administrator shall determine. Certificates or book entries evidencing shares of Restricted Stock must include an appropriate legend referring to the terms, conditions, and restrictions applicable to such Restricted Stock. The Company may, in its sole discretion, (a) retain physical possession of any stock certificate evidencing shares of Restricted Stock until the restrictions thereon shall have lapsed and/or (b) require that the stock certificates evidencing shares of Restricted Stock be held in custody by a designated escrow agent (which may but need not be the Company) until the restrictions thereon shall have lapsed, and that the grantee deliver a stock power, endorsed in blank, relating to such Restricted Stock.
(c)
Restrictions. Restricted Stock may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided herein or in the Restricted Stock Award Certificate. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 18 below, in writing after the Award is issued, if a grantee’s employment (or other service relationship) with the Company and its Subsidiaries terminates for any reason, any Restricted Stock that has not vested at the time of termination shall automatically and without any requirement of notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price (if any) from such grantee or such grantee’s legal representative simultaneously with such termination of employment (or other service relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of unvested Restricted Stock that are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration.
(d)
Vesting of Restricted Stock. The Administrator at the time of grant shall specify the date or dates and/or the attainment of pre-established performance goals, objectives and other conditions on which the non-transferability of the Restricted Stock and the Company’s right of repurchase or forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such pre-established performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall no longer be Restricted Stock and shall be deemed “vested.” Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 18 below, in writing after the Award is issued, a grantee’s rights in any shares of Restricted Stock that have not vested shall automatically terminate upon the grantee’s termination of employment (or other service relationship) with the Company and its Subsidiaries and such shares shall be subject to the provisions of Section 7(c) above.
SECTION 8.
RESTRICTED STOCK UNITS
(a)
Nature of Restricted Stock Units. The Administrator shall determine the restrictions and conditions applicable to each Restricted Stock Unit at the time of grant. Conditions may be based on continuing employment (or other service relationship) and/or achievement of pre-established performance goals and objectives. The terms and conditions of each such Award Certificate shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. Upon vesting, the Restricted Stock Units shall be settled in the form of shares of Stock. To the extent that an award of Restricted Stock Units is subject to Section 409A, it may contain such additional terms and conditions as the Administrator shall determine in its sole discretion in order for such Award to comply with the requirements of Section 409A.
(b)
Election to Receive Restricted Stock Units in Lieu of Compensation. The Administrator may, in its sole discretion, permit a grantee to elect to receive a portion of future cash compensation otherwise due to such grantee in the form of an award of Restricted Stock Units. Any such election shall be made in writing and shall be delivered to the Company no later than the date specified by the Administrator and in accordance with Section 409A and such other rules and procedures established by the Administrator. Any such future cash compensation that the grantee elects to receive in the form of Restricted Stock Units shall be converted to a fixed number of Restricted Stock Units based on the Fair Market Value of Stock on the date the compensation would otherwise have been paid to the grantee if grantee had not elected to receive such payment in the form of Restricted Stock Units. The Administrator shall have the sole right to determine whether and under what circumstances to permit such elections and to impose such limitations and other terms and conditions thereon as the Administrator deems appropriate. The Administrator shall determine the terms and conditions applicable to any Restricted Stock Units that are elected to be received in lieu of cash compensation.
(c)
Rights as a Stockholder. A grantee shall have the rights as a stockholder only as to shares of Stock acquired by the grantee upon settlement of Restricted Stock Units; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the Restricted Stock Units, subject to such terms and conditions as the Administrator may determine.

 


 

(d)
Termination. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 18 below, in writing after the Award is issued, a grantee’s right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee’s termination of employment (or cessation of service relationship) with the Company and its Subsidiaries for any reason.
SECTION 9.
UNRESTRICTED STOCK AWARDS
(a)
Grant or Sale of Unrestricted Stock. The Administrator may, in its sole discretion, grant (or sell at par value or such higher purchase price determined by the Administrator) an Unrestricted Stock Award under the Plan. Unrestricted Stock Awards may be granted in respect of past services or other valid consideration, or in lieu of cash compensation due to such grantee.
SECTION 10.
CASH-BASED AWARDS
(a)
Grant of Cash-Based Awards. The Administrator may, in its sole discretion, grant Cash-Based Awards to any grantee in such number or amount and upon such terms, and subject to such conditions, as the Administrator shall determine at the time of grant. The Administrator shall determine the maximum duration of the Cash-Based Award, the amount of cash to which the Cash-Based Award pertains, the conditions upon which the Cash-Based Award shall become vested or payable, and such other provisions as the Administrator shall determine. Each Cash-Based Award shall specify a cash-denominated payment amount, formula or payment ranges as determined by the Administrator. Payment, if any, with respect to a Cash-Based Award shall be made in accordance with the terms of the Award and may be made in cash or in shares of Stock, as the Administrator determines.
SECTION 11.
PERFORMANCE SHARE AWARDS
(a)
Nature of Performance Share Awards. The Administrator may, in its sole discretion, grant Performance Share Awards independent of, or in connection with, the granting of any other Award under the Plan. The Administrator shall determine whether and to whom Performance Share Awards shall be granted, the Performance Goals, the periods during which performance is to be measured, and such other limitations and conditions as the Administrator shall determine.
(b)
Rights as a Stockholder. A grantee receiving a Performance Share Award shall have the rights of a stockholder only as to shares actually received by the grantee under the Plan and not with respect to shares subject to the Award but not actually received by the grantee. A grantee shall be entitled to receive shares of Stock under a Performance Share Award only upon satisfaction of all conditions specified in the Performance Share Award Certificate (or in a performance plan adopted by the Administrator).
(c)
Termination. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 18 below, in writing after the Award is issued, a grantee’s rights in all Performance Share Awards shall automatically terminate upon the grantee’s termination of employment (or cessation of service relationship) with the Company and its Subsidiaries for any reason.
SECTION 12.
[RESERVED]
SECTION 13.
DIVIDEND EQUIVALENT RIGHTS
(a)
Dividend Equivalent Rights. A Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Stock Units, Restricted Stock Award or Performance Share Award or as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Certificate. Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents. Any such reinvestment shall be at Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof, in a single installment or installments. A Dividend Equivalent Right granted as a component of an award of Restricted Stock Units, Restricted Stock Award or Performance Share Award may provide that such Dividend Equivalent Right shall be settled upon settlement or payment of, or lapse of restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award. A Dividend Equivalent Right granted as a component of a Restricted Stock Units, Restricted Stock Award or Performance Share Award may also contain terms and conditions different from such other Award.

 


 

(b)
Interest Equivalents. Any Award under this Plan that is settled in whole or in part in cash on a deferred basis may provide in the grant for interest equivalents to be credited with respect to such cash payment. Interest equivalents may be compounded and shall be paid upon such terms and conditions as may be specified by the grant.
(c)
Termination. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 18 below, in writing after the Award is issued, a grantee’s rights in all Dividend Equivalent Rights or interest equivalents granted as a component of an award of Restricted Stock Units, Restricted Stock Award or Performance Share Award that has not vested shall automatically terminate upon the grantee’s termination of employment (or cessation of service relationship) with the Company and its Subsidiaries for any reason.
SECTION 14.
TRANSFERABILITY OF AWARDS
(a)
Transferability. Except as provided in Section 14(b) below, during a grantee’s lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee’s legal representative or guardian in the event of the grantee’s incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be null and void.
(b)
Administrator Action. Notwithstanding Section 14(a), the Administrator, in its discretion, may provide either in the Award Certificate regarding a given Award or by subsequent written approval that the grantee (who is an employee or member of the Board) may transfer his or her Awards (other than any Incentive Stock Options or Restricted Stock Units) to his or her immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award. In no event may an Award be transferred by a grantee for value.
(c)
Family Member. For purposes of Section 14(b), “family member” shall mean a grantee’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the grantee’s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50 percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50 percent of the voting interests.
(d)
Designation of Beneficiary. Each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee’s death. Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee’s estate.
SECTION 15.
TAX WITHHOLDING

To the extent required by applicable federal, state, local or foreign law, the Administrator may and/or a Participant shall make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise with respect to any Award, or the issuance or sale of any shares of Stock. The Company shall not be required to recognize any Participant’s rights under an Award, to issue shares of Stock or to recognize the disposition of such shares of Stock until such obligations are satisfied. To the extent permitted or required by the Administrator, these obligations may or shall be satisfied by the Company withholding cash from any compensation otherwise payable to or for the benefit of a Participant, the Company withholding a portion of the shares of Stock that otherwise would be issued to a Participant under such Award or any other award held by the Participant or by the Participant tendering to the Company cash or, if allowed by the Administrator, shares of Stock.

SECTION 16.
SECTION 409A AWARDS

To the extent that any Award is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A (a “409A Award”), the Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply with Section 409A. In this regard, if any amount under a 409A Award is payable upon a “separation from service” (within the meaning of Section 409A) to a grantee who is then considered a “specified employee” (within the meaning of Section 409A), then no such payment shall be made prior to the

 


 

date that is the earlier of (i) six months and one day after the grantee’s separation from service, or (ii) the grantee’s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section 409A. Further, the settlement of any such Award may not be accelerated except to the extent permitted by Section 409A.

SECTION 17.
TRANSFER, LEAVE OF ABSENCE, ETC.

For purposes of the Plan, the following events shall not be deemed a termination of employment:

(a)
a transfer to the employment of the Company from a Subsidiary or from the Company to a Subsidiary, or from one Subsidiary to another Subsidiary; or
(b)
an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee’s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing.
SECTION 18.
AMENDMENTS AND TERMINATION

The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall adversely affect rights under any outstanding Award without the holder’s consent. To the extent required under the rules of any securities exchange or market system on which the Stock is listed, to the extent determined by the Administrator to be required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section 422 of the Code, Plan amendments shall be subject to approval by the Company stockholders entitled to vote at a meeting of stockholders. Nothing in this Section 18 shall limit the Administrator’s authority to take any action permitted pursuant to Section 3(b) or 3(c).

SECTION 19.
STATUS OF PLAN

The Plan is intended to constitute an “unfunded” plan. With respect to any payment as to which a Participant has a fixed and vested interest but which are not yet made to a Participant by the Company, nothing contained herein shall give any such Participant any right that is greater than those of a general unsecured creditor of the Company.

SECTION 20.
GENERAL PROVISIONS
(a)
Legend. The Administrator may require each person receiving shares of Stock pursuant to an Award under the Plan to represent to and agree with the Company in writing that the Participant is acquiring the shares without a view to distribution thereof. In addition to any legend required by the Plan, the certificates for such shares may include any legend that the Administrator deems appropriate to reflect any restrictions on transfer. All certificates for shares of Stock delivered under the Plan shall be subject to such stop transfer orders and other restrictions as the Administrator may deem advisable under the rules, regulations and other requirements of the Securities and Exchange Commission, any stock exchange upon which the Stock is then listed or any national securities exchange system upon whose system the Stock is then quoted, any applicable federal or state securities law, and any applicable corporate law, and the Administrator may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.
(b)
Other Compensation Arrangements; No Employment Rights. Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any employee any right to continued employment with the Company or any Subsidiary.
(c)
No Right to Same Benefits. The provisions of Awards need not be the same with respect to each Participant, and such Awards to individual Participants need not be the same in subsequent years.
(d)
Other Benefit. No Award granted or paid out under the Plan shall be deemed compensation for purposes of computing benefits under any retirement plan of the Company or its Subsidiaries nor affect any benefit under any other benefit plan now or subsequently in effect under which the availability or amount of benefits is related to the level of compensation, except to the extent legally required pursuant to the terms of such plan.

 


 

(e)
Trading Policy Restrictions. Option exercises and other Awards under the Plan shall be subject to the Company’s insider trading policies and procedures, as in effect from time to time.
(f)
Forfeiture of Awards under Sarbanes-Oxley Act. If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company, as a result of misconduct, with any financial reporting requirement under the securities laws, then any grantee who is one of the individuals subject to automatic forfeiture under Section 304 of the Sarbanes-Oxley Act of 2002 shall reimburse the Company for the amount of any Award received by such individual under the Plan during the 12-month period following the first public issuance or filing with the United States Securities and Exchange Commission, as the case may be, of the financial document embodying such financial reporting requirement.
SECTION 21.
EFFECTIVE DATE OF PLAN

The Plan, as most recently amended, was approved by the Board on May 2, 2024 and shall become effective on the date it is approved by the stockholders of the Company (the “Effective Date”). Subject to earlier termination as provided in Section 18, no new Awards may be granted under the Plan on or after the 10th year anniversary of approval by the stockholders; provided, however, that Awards outstanding on such date shall remain subject to the terms of the Plan and any applicable Award Certificate; and, provided, further, that Incentive Stock Options may not be granted under the Plan after the 10th year anniversary of the date of the Board’s approval of the Plan.

SECTION 22.
GOVERNING LAW

This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with, the laws of the State of Delaware, applied without regard to conflict of law principles.

 


EX-101.SCH 4 atos-20240627.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Entity Addresses, Address Type [Axis] Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Document Information [Table] Entity Central Index Key Entity Address, State or Province Cover [Abstract] Entity Address, Address Line One Amendment Flag Entity Address, City or Town Document Type Title of 12(b) Security Address Type [Domain] Former Address [Member] Soliciting Material Document Period End Date Trading Symbol Pre-commencement Tender Offer Security Exchange Name Written Communications Pre-commencement Issuer Tender Offer Current Fiscal Year End Date Entity Registrant Name Entity Emerging Growth Company Entity File Number Entity Tax Identification Number City Area Code Local Phone Number Document Information [Line Items] XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Document And Entity Information
Jun. 27, 2024
Document Information [Line Items]  
Entity Registrant Name Atossa Therapeutics, Inc.
Document Type 8-K
Document Period End Date Jun. 27, 2024
Entity Incorporation, State or Country Code DE
Entity File Number 001-35610
Entity Tax Identification Number 26-4753208
Entity Address, Address Line One 10202 5th Avenue NESuite 200
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98125
City Area Code 206
Local Phone Number 588-0256
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Title of 12(b) Security Common Stock
Trading Symbol ATOS
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001488039
Current Fiscal Year End Date --12-31
Former Address [Member]  
Document Information [Line Items]  
Entity Address, Address Line One 107 Spring Street
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98104
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 2 23 1 false 1 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports atos-20240627.htm atos-20240627.xsd http://xbrl.sec.gov/dei/2024 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "atos-20240627.htm": { "nsprefix": "atos", "nsuri": "http://atossatherapeutics.com/20240627", "dts": { "inline": { "local": [ "atos-20240627.htm" ] }, "schema": { "local": [ "atos-20240627.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 2, "entityCount": 1, "segmentCount": 1, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 27 }, "report": { "R1": { "role": "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_8ba69cba-50b9-47af-9129-49cab58ca8c2", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "atos-20240627.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8ba69cba-50b9-47af-9129-49cab58ca8c2", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "atos-20240627.htm", "first": true, "unique": true } } }, "tag": { "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r6", "r7" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://atossatherapeutics.com/20240627/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r8" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-24-080497-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-080497-xbrl.zip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�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
XML 15 atos-20240627_htm.xml IDEA: XBRL DOCUMENT 0001488039 2024-06-27 2024-06-27 0001488039 dei:FormerAddressMember 2024-06-27 2024-06-27 0001488039 --12-31 false 8-K 2024-06-27 Atossa Therapeutics, Inc. DE 001-35610 26-4753208 10202 5th Avenue NESuite 200 Seattle WA 98125 206 588-0256 107 Spring Street Seattle WA 98104 false false false false Common Stock ATOS NASDAQ false